Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials
J Am Heart Assoc. 2026 Sep 9:e044249. doi: 10.1161/JAHA.125.044249. Online ahead of print.ABSTRACTBACKGROUND: Tirzepatide is a dual agonist for glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, with proven efficacy in weight loss and improvement in cardiovascular ou

